MedAI Verdict
Radiology

AI Radiology

Nanox.AI logo

Nanox.AI

by Nano-X Imaging

Last verified

CT AI for opportunistic screening: coronary calcium, vertebral fractures and liver fat on routine CT scans, for radiology departments.

Visit Nanox.AI (opens in new tab)Read our methodology

At a glance

Pricing
No public price.
HIPAA
Not disclosed
SOC 2
Not disclosed
EHRs
—
Founded
—
On this page

Independent score  ·  By our public rubric

35/100Competitive

Editorial rating 2.5 / 5

How it’s computed →
  • Regulatory & Compliance
    18/28

    FDA cleared (12 K-numbers on record)

  • Clinical Integration
    0/6.6

    No EHR integrations listed

  • Evidence Strength
    0/26

    No peer-reviewed coverage

  • Vendor & Market
    8.4/18

    Mid-tier funding and adoption

  • Sentiment & Transparency
    2.5/5

    Pricing on request, no public amounts

▸ Show all 11 dimensions

Regulatory & Compliance

  • FDA clearance18/18

    FDA cleared (12 K-numbers on record)

  • HIPAA / SOC2 / BAA0/10

    No public HIPAA/SOC2/BAA attestation

Clinical Integration

  • EHR integrations (count)0/4

    No EHR integrations listed

  • Top-3 EHR coverage (Epic / Oracle / Athena)0/2

    None of the top-3 EHRs covered

Evidence Strength

  • Peer-reviewed papers0/18

    No peer-reviewed coverage

  • RCT / meta-analysis / systematic review0/8

    No RCT, meta-analysis, or systematic review

Vendor & Market

  • Funding & adoption signal8/12

    Mid-tier funding and adoption

  • Years in market0/6

    Founded year not recorded

Sentiment & Transparency

  • Pricing transparency3/5

    Pricing on request, no public amounts

Scored November 2, 2026 · Public scoring method v1.2.0

CT AI for opportunistic screening: coronary calcium, vertebral fractures and liver fat on routine CT scans, for radiology departments.

No public price.

Evidence record

FDA decisions
Show 7 more
Verification
  • Score computed November 2, 2026, method 1.2.0
  • Review written November 2, 2026
Cite this record

MedAI Verdict, Nanox.AI record, https://medaiverdict.com/tools/nanox-ai, version November 2, 2026

Change history
View every change to this record

Bottom line

Nanox.AI is a set of CT algorithms for opportunistic screening: they read scans acquired for other reasons and look for unrecognized chronic disease. The three products on the current AI page measure coronary calcium, vertebral height loss with bone density, and liver density. Radiology departments with heavy CT volume and a cardiac, bone or fatty-liver detection program are the audience. The older triage lines that appear in FDA records, such as pneumothorax and head hemorrhage triage, are absent from the current page, and whether they are still sold is not stated.

Whose name is on the FDA records?

The AI unit appears in FDA records as Zebra Medical Vision, Ltd. for 2018 to 2021, as Nanoxai, Ltd. in 2022 and as Nano-X AI, Ltd. in 2024. Whether Nanox acquired Zebra Medical Vision is unconfirmed. The Nasdaq-listed parent, Nano-X Imaging Ltd., files its hardware under a separate applicant, and those devices are not AI products.

What do the three tools measure?

HealthCCSng analyzes non-contrast, non-ECG-gated chest CT and measures calcified plaque in the coronary arteries, returning a calcium category. The vendor page ties the numerical score to the V.2 clearance. HealthOST detects vertebral height loss and measures bone mineral density on chest and abdominal CT. HealthFLD reports liver density in Hounsfield units on CT that covers a significant part of the liver, for fatty liver (MASLD/NAFLD) and MASH. According to the vendor, results go into the radiology report and the EMR.

How do the vendor's count and FDA's differ?

The AI page counts 7 FDA clearances and 2 CE Marks. FDA records show 12 AI decisions, from June 2018 to August 2024, filed under the three applicant names and including the older product lines. The current suite accounts for four of them: HealthOST in April 2022, HealthFLD in February 2024, and HealthCCSng in September 2021 and August 2024. The August 2024 decision covers routine non-gated, non-contrast CT in adults 30 to 85, with an exact calcium score and a four-category output.

What do the studies show?

A 2025 validation in Diagnostics (PMID 40564850) tested HealthOST for incidental vertebral compression fractures on outpatient chest and abdomen CT. Sensitivity was 92.0% at the 20% height-loss threshold, and the specificity figures in the abstract start at 52.7%. A 2025 BJR Artificial Intelligence paper (PMID 42064007) covers deploying the Nanox vertebral fracture solution in five NHS hospitals and concerns governance, not accuracy.

The vendor's AI page carries a case study from Corewell Health reporting nearly 4,000 new patients with coronary calcification in 2023, against 268 in the prior two years. It is vendor-published and not peer reviewed.

What does buying involve?

No public price. The AI page offers a meeting booking and a US Reimbursement Demo.

The verdict

The three current tools fit a radiology department that wants coronary calcium, vertebral height loss and liver density from CT it already acquires. A department after worklist triage for pneumothorax or head bleeds is outside what the current page lists.

Editorial review last generated November 2, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.

What it costs

All tiers are custom-quoted. The vendor does not publish per-provider list pricing.

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price.

Source: vendor pricing page. Last checked November 2, 2026.

What deploys cleanly

Carries FDA 510(k), CE per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.

Other radiology

See the full radiology ranking